174 results about "Rhinovirus" patented technology

The present invention relates to pharmaceutical compositions for delivery of drugs intended to reside in the nose, compositions for nasal administration of drugs, e.g., antiviral agents, and particularly antiviral agents comprising the human major rhinovirus receptor, also known as intercellular adhesion molecule-1 (ICAM-1); to methods of making said nasal drug compositions, and to an improved process for the removal of residual solvent from pharmaceutical matrices.

Frequent application of a virucidal hand lotion containing malic acid, citric acid, and a C1-6 alcohol will prevent the hand-to-hand transmission of rhinoviruses and reduce the incidence of the "common cold" caused by rhinoviruses.

The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Picornaviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of Enterovirus and/or Rhinovirus infection in a mammal. The antisense antiviral compounds are substantially uncharged, including partially positively charged, morpholino oligonucleotides have a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with viral RNA sequences within a 32 nucleotide region of the viral 5′ untranslated region identified by SEQ ID NO:4.

The invention belongs to the technical fields of biochips and diagnostic reagents, and discloses a method for detecting various respiratory viruses, and primers and probes thereof. In the invention, nucleotide sequences of 14 respiratory viruses, namely adenovirus, human metapneumovirus, influenza virus A, influenza virus B, respiratory syncytial virus, bocavirus, rhinovirus, coronavirus (HKU1, NL63 and SARS), and parainfluenza virus (type I, type II, type III and type IV) are analyzed, and corresponding reverse transcription primers, PCR primers and specific probes are designed. Specific gene segments are amplified by reverse transcription and multiple asymmetric PCR methods; a fluorescence-coded microsphere group coupled with the virus specific probes and the PCR amplification product are incubated and hybridized by liquid phase chip technology; and finally the Bio-PlexTM200 is used for detection. The detection method has the advantages of high flux, high specificity and sensitivity, stable results and good repeatability, the detection method is easy to operate, and the detection speed is high.

Antimicrobial compositions that provide enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, coronovirus, respiratory syncytial virus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, antimicrobial compositions comprising an organic acid or organic acid mixture and a short-chain anionic surfactant having at least one of a large head group; a branched alkyl chain and an unsaturated alkyl chain. Further, products incorporating the antimicrobial compositions of the present invention and methods of using the antimicrobial compositions and products are disclosed herein.

Therapeutic antimicrobial compositions and methods for providing enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, coronovirus, respitory syricytial virus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, therapeutic antimicrobial compositions comprising an organic acid or organic acid mixture and a short-chain anionic surfactant having at least one of a large head group; a branched alkyl chain and an unsaturated alkyl chain, and therapeutic methods of use thereof.

Antiviral protease inhibitors, including peptidyl aldehydes, peptidyl α-ketoamides, peptidyl bisulfite salts, and peptidyl heterocycles, are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.

The invention discloses a method for simultaneously detecting twelve kinds of common respiratory viruses. According to the method, primers and probes are designed according to gene conservative areas of the twelve kinds of common respiratory viruses, namely influenza A virus, influenza B virus, influenza C virus, parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, rhinovirus, Bocavirus, adenovirus, coronavirus, metapneumovirus and respiratory syncytial virus, nucleic acid fragments of samples to be measured are extracted for amplifying, and finally, the samples are separated by using a capillary electrophoresis method. The method disclosed by the invention has the advantages of low required sample size, high sensitivity and accuracy, good specificity and low cost; the defects that the conventional single tube multiplex fluorescence PCR (Polymerase Chain Reaction) detection primers are difficult to design, and multicolor fluorescence mutually intervenes and is not easy to part are overcome, the defects that a chip detection method is tedious in operation, high in detection cost and the like are also overcome, and a new method is provided for screening the respiratory viruses.

The present invention provides an immunogenic composition comprising: (a) an isolated recombinant chimeric human rhinovirus, wherein the recombinant chimeric human rhinovirus comprises (i) a nucleic acid having a nucleotide sequence of a human rhinovirus encoding at least a portion of a human rhinovirus capsid; (ii) a heterologous nucleic acid having a nucleotide sequence encoding a chimeric region, wherein the chimeric region is expressed on the surface of the chimeric rhinovirus and is capable of participating in an immune reaction; and (iii)a pharmaceutically acceptable carrier.

The present invention relates to a novel nasal formulation for the treatment and prophylaxis of nasal congestion. When an infant is born, its nasal passages are relatively sterile, in time the nasal passages are colonized by fungi, molds and other organisms which compromise the integrity of the nasal and paranasal mucosa. The presence of these organisms elicits a mild chronic inflammatory reaction of the nasal and paranasal mucosa, in some cases leading to congestion and excess production of mucus. This chronic inflammatory process compromises the integrity of the nasal and paranasal mucosa, making it more vulnerable to binding with allergens and other invading organisms such as the rhinovirus. The purpose of this invention is to establish a treatment and prophylaxis of nasal congestion, which will control the presence of the invading organisms in the nasal and paranasal mucosa, reducing congestion as well as mucus production. By reducing the mild chronic inflammation in the nasal passages, prophylaxis with this nasal formulation passively reestablishes the integrity of the nasal and paranasal mucosa, thereby reinforcing the body's defenses against the implantation of allergens and of organisms such as the rhinovirus.

The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I).

The present invention relates to the use of imatinib for treating viral liver diseases and in particular for viral hepatitis. The invention provides the use of imatinib for inhibiting replication, transmission or both of hepatitis viruses. The invention further relates to the use of imatinib for inhibiting replication, transmission or both of other viruses including herpes virus, poxvirus, influenza virus, para influenza virus, respiratory syncytial virus, rhinovirus, yellow fever virus, west nile virus, and encephalitis virus.

The invention discloses a high-flux non-diagnostic detection method for 13 respiratory viruses based on a novel suspension chip technology. Aiming at the specificity gene sequences of 13 pieces or types of respiratory viruses, such as influenza viruses A and B, auxiliary influenza viruses 1 and 3, coronavirus SARS-CoV and CoV-NL63, respiratory syncytial viruses A and B, adenoviruses B and E, a rhinovirus, a human metapneumovirus and an enterovirus, 13 pairs of primers and corresponding specificity probes are designed; by multiple polymerase chain reaction (PCR) amplification and TSPE reaction, X-TAG nucleic acid fragment and biotin are respectively marked with corresponding gene fragments; the marked fragments are combined with corresponding encoded micro balls; and a suspension chip scanner is used for performing detection. The high-flux non-diagnostic detection method can accurately detect 13 respiratory viruses and subtypes of the 13 respiratory viruses; the probes do not generate cross reaction; the specificity is high; and the sensitivity is high. A high-flux, quick and accurate technical platform is capable of simultaneously detecting various respiratory viruses; technical equipment is supplied to the detection of pathogens of sudden respiratory tract infectious diseases; and information can be timely supplied to the handling of infectious disease epidemic situation burst.

The invention discloses L-nucleoside compounds having the structure characteristic represented by the formula (I) or pharmaceutically acceptable salts thereof, and belongs to the technical field of pharmaceutical chemistry. The compounds can inhibit the activity of RNA viral polymerase, so the compounds can be used as potential drugs for prevention and treatment of infection of RNA viruses such as HCV, influenza virus, HRV (rhinovirus), RSV, Ebola virus, dengue virus, intestinal virus and the like.

The invention relates to probes and assays which are used for the simultaneous detection, in a single assay sample, of a plurality of nucleic acid sequences of viruses that cause respiratory infections in humans, selected from among influenza virus type A, influenza virus type B, influenza virus type C, human respiratory syncytial virus type A, human respiratory syncytial virus type B, human adenovirus, human parainfluenza virus type 1, human parainfluenza virus type 2, human parainfluenza virus type 3, human parainfluenza virus types 4A and 4B, enterovirus, rhinovirus, human coronavirus type 229E, human coronavirus type OC43, coronavirus that causes severe acute respiratory syndrome (SARS), human metapneumovirus and combinations thereof.

Belonging to the molecular biology field, the invention relates to a primer set for respiratory tract infection pathogen detection, a rapid diagnostic kit and a detection method. The primer set can achieve one-time detection of the following 9 respiratory tract infection pathogens: influenza A virus, influenza B virus, respiratory syncytial virus, parainfluenza virus type I, parainfluenza virus type II and parainfluenza virus type III, adenovirus, mycoplasma pneumonia, legionella pneumonia, chlamydia pneumonia and human rhinovirus. The invention adopts solid phase recombinase-polymerase constant temperature gene amplification method to detect respiratory multiple infection pathogens. The primer set adopted by the invention for respiratory tract infection pathogen detection has strong specificity and high amplification efficiency, can effectively and rapidly detect the 9 pathogens simultaneously, and realizes multiplex detection.

The invention discloses a double-fluorescent PCR detection primer, a probe, reaction liquid and a kit capable of rapidly detecting 16 pathogens of the respiratory tract. The kit comprises pre-subpackaged PCR reaction liquid, RT-PCR enzyme, a positive quality control product and a negative quality control product, wherein the pre-subpackaged PCR reaction liquid is provided with a primer and a TaqMan probe for detecting at least two of the following pathogens: respiratory syncytial virus, enterovirus, coronavirus NL63, coronavirus HKU1, coronavirus 229E, coronavirus OC43, parainfluenza virus type I, parainfluenza virus type II, rhinovirus, parainfluenza virus type III, human bocavirus, human metapneumovirus, mycoplasma pneumoniae, chlamydia pneumoniae, adenovirus and legionella pneumophila. The kit is convenient to operate, and can be used for at most screening 16 syndrome pathogens of the respiratory tract within 2 hours, so that the detection time and cost are greatly saved. The kit has the greatest advantages of simplicity in operation and strong practicability, and can be easily popularized in laboratories of the ports.

The present invention discloses a medicine with obvious antiviral effect for resisting coxsackie virus, adenovirus Ad7, parafinflueza virus and rhinovirus. Said invention also provides the general formula of said medicine.